Navigation Links
Tosoh Bioscience Introduces TSK-GEL SP-3PW (30), a Higher-Capacity Resin for the Purification of Insulin and Other Therapeutic Peptides and Small Proteins
Date:5/25/2010

Contains a smaller pore for improved resolution combined with unique selectivity and higher capacity than TSK-GEL SP-5PW resin for purification of insulin and other peptides and small proteins.

King of Prussia, PA (PRWEB) May 25, 2010 -- Tosoh Bioscience LLC, a provider of chromatographic solutions for biopurification, recently announced the introduction of a new line of TSK-GEL SP-3PW (30) resins for use in large scale purification of peptides and proteins. Packaging container volumes vary from 100mL up to 50L.

The TSK-GEL SP-3PW (30) resin is manufactured with a new production technology which yields a narrower particle size distribution. The 250Å pore of the particles is ideal for insulin and similarly sized molecules. The smaller pore size coupled with a higher ligand density account for the higher capacity over TSK-GEL 5PW resins.

The new polymer technology creates an additional selectivity tool for use by the developer for demanding separation problems. TSK-GEL SP-3PW (30) resins can be used for both polishing and intermediate purification process steps.

According to Al Jackewitz, marketing manager of process development resins at Tosoh Bioscience LLC, the new resin can be made in larger batches than the other TSK-GEL SP-5PW resins, and the new technology may be applied to other ligands in the near future.

The new resin is in inventory and now available for purchase.

TOSOH BIOSCIENCE LLC

Tosoh Bioscience LLC provides liquid chromatography products to laboratories and manufacturing plants in the Americas. While the majority of our customers are employed in biotechnology and pharmaceutical companies, our HPLC columns and systems are essential tools for sample analysis in most industries. Our dedicated size-exclusion HPLC system is predominantly used in the chemical and electronic industries. In the field of biotechnology, our preparative chromatography resins play a critical role in the purification of proteins and nucleic acids for medical purposes.

The company is a subsidiary of Tosoh Corporation in Japan, the parent of the Tosoh Group, which comprises 141 companies worldwide and a multiethnic workforce of over 10,000 people and generates sales of ¥827 billion (US$8.3 billion) annually.

For more information, please contact
Al Jackewitz
Biopurification Market Manager
Tosoh Bioscience LLC
484-805-1219

###

Read the full story at http://www.prweb.com/releases/2010/05/prweb4043554.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
2. YM BioSciences announces presentations on global nimotuzumab trials at ASCO annual meeting
3. YM BioSciences third quarter 2010 operational and financial results
4. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
5. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
6. YM BioSciences announces controlled equity offering
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
8. NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
9. Bioscience Bridge, LLC Launches as a Technology Transfer Agency for University-Based Bioscience Research
10. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
11. YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Tosoh Bioscience Introduces TSK-GEL SP-3PW (30), a Higher-Capacity Resin for the Purification of Insulin and Other Therapeutic Peptides and Small Proteins 
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
(Date:6/22/2016)... 2016 Research and Markets has announced the ... to their offering. The ... $29.3 billion in 2013. The market is expected to grow at ... to 2020, increasing from $50.6 billion in 2015 to $96.6 billion ... the forecast period (2015 to 2020) are discussed. As well, new ...
(Date:6/22/2016)... ... June 21, 2016 , ... New light-based technologies that facilitate a “look inside” ... to enable both compact, wearable devices for point-of-care diagnostics as well as powerful new ... Recent work and visionary future directions are detailed in a new open-access article by ...
Breaking Biology Technology:
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
Breaking Biology News(10 mins):